IQVIA

Market Reflection Report

October 2024

11th November

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Disclaimer

IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide
investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001

The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies,
caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No
warranty is made as to the completeness or accuracy of such third party sources or data

This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase or not purchase,
an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entity

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to
certain risks and uncertainties, and are not to be considered guarantees of any particular outcome

This report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report, without IQVIA’
prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, including
this complete Disclaimer page

This report is subject to the IQVIA General Terms and Conditions.

1
 IPM Overview
TSA SSA
Growth %%

30 30
2021-22 2021-22
20 20
2022-23 2022-23
10 10
2023-24 2023-24
0 0
-10 -10
Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct

TSA IPM Trends (Value Rs. 226,217 Crs) – MAT Oct'24 SSA IPM Trends (Value Rs. 190,940 Crs) – MAT Oct'24

5.0%
4.5%
6.8%
6.7%
MAT
226,217 MAT
Month 190,940
211,724 Month
178,938
189,866
178,997 160,932
151,724

15,779 16,314 19,003 19,957 13,369 13,857 16,116 16,843

2021 2022 2023 2024 2021 2022 2023 2024

• TSA valued at Rs. 226,217 Cr with growth of 6.8% as of MAT Oct'24 and Rs 19,957 Cr for Oct'24 month with growth of 5.0%
• SSA valued at Rs. 190,940 Cr with growth of 6.7% as of MAT Oct'24 and Rs 16,843 Cr for Oct'24 month with growth of 4.5%

IQVIA TSA & SSA Dataset Oct'24 2

 Amongst top 10 contributing therapies, Cardiac followed by ADB
posted highest growth while AI & Respiratory are degrowing
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)
8 8 10 10 7 12 8
IPM 19,957 3 5 1 5 5
IPM
12 13 16 13 14 11 13
6 8 8 9 10
CARDIAC 2,511 CARDIAC
10 9 15 10
2 0 1 -2 2 0 -5
AI 2,340 -8
AI
11 13 15
6 9 7 10 9 6
GI 2,034 5 6 GASTRO
1
9 10 11 8 11 8 8 10
ANTI-DIAB 1,738 2 5 3 4 A.DIAB
3 1 5 2 7
-2 -2 -8 -1 -1 -2
RESPI 1,679 3
RESPI
9 8 8 10 7 11 7
PAIN 1,612 3 5 1 5 5
PAIN

VMN 1,553 8 9 10 10 12 7
3 5 3 6 5 5
VMN
11 12 11 12 9 9
5 8 6 6 8
DERMA 1,396
-2 DERMA
1,187 8 10 11 12 8 7 8
NEURO 6 6 6 7 7
NEURO
5 7 9 7 7 3 4 3
GYNAEC 936 1 0 2 1
28 GYNAEC
26 20 25 13 23 19 20 14 14
ONCO 516 10 11
ONCO
11 12
16 17 15 14
UROLOGY 438 8 11 12 URO
17 14
9
Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct
3
IQVIA TSA & SSA Dataset Oct'24 Therapy sorted on Month
 Top Companies #1-10 Market Share Trend
9

TSA Val Oct'24 MS Oct'24

8 SUN* 1,576 7.90
ABBOTT* 1,258 6.30
7 CIPLA 1,073 5.38
(MANKIND) 883 4.42
(ALKEM*) 818 4.10
6
INTAS* 725 3.63
TORRENT 680 3.41
5
LUPIN 673 3.37
(MACLEODS) 672 3.37
4 (DRL) 605 3.03

2
Oct’23 Nov’23 Dec’23 Jan’24 Feb’24 Mar’24 Apr’24 May’24 Jun’24 Jul’24 Aug’24 Sep’24 Oct’24

• Sun*, Abbott*, Cipla, Intas*, Torrent & Lupin have shown improvement in MS for Oct'24 as compared to Sep’24
• Mankind, Alkem*, Macleods & DRL reflected dip in MS for Oct'24 as compared to Sep'24

IQVIA TSA & SSA Dataset Oct'24 4

 Top Companies #1-10
TSA SSA

Value
Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI
(Rs. Crs)
SUN* 1,576 10 105 SUN* 1,329 10 105
ABBOTT* 1,258 9 104 ABBOTT* 1,072 8 103
CIPLA 1,073 6 101 CIPLA 917 6 102
MANKIND 883 1 97 MANKIND 797 1 97
Month

Month
ALKEM* 818 1 97 ALKEM* 724 2 97
INTAS* 725 9 104 TORRENT 602 10 105
TORRENT 680 9 104 MACLEODS 597 -2 94

LUPIN 673 7 102 INTAS* 591 9 105

MACLEODS 672 -2 93 LUPIN 580 8 104

8 103 ARISTO* 523 -8 88
DRL 605

SUN* 17,730 9 102 SUN* 14,990 8 102

ABBOTT* 14,054 8 101 ABBOTT* 12,095 8 102
CIPLA 12,332 7 100 CIPLA 10,581 9 102
MANKIND 10,057 8 101 MANKIND 9,081 8 101
MAT

97 99

MAT
ALKEM* 8,876 4 ALKEM* 7,838 5
INTAS* 8,211 11 104 TORRENT 6,872 9 102
LUPIN 7,781 7 100 LUPIN 6,693 8 101
TORRENT 7,759 8 101 MACLEODS 6,638 6 99
MACLEODS 7,491 6 99 INTAS* 6,630 10 103
DRL 7,021 8 102 DRL 5,864 9 102

• TSA & SSA : Sun showed the highest growth at month level, while for MAT, Intas has posted highest growth

IQVIA TSA & SSA Dataset Oct'24

5
 Top Companies #11-20 Market Share Trend
3.4

3.2
TSA Val Oct'24 MS Oct'24
3.0
(ARISTO*) 578 2.90
2.8
(ZYDUS*) 562 2.82
2.6 EMCURE* 458 2.29
2.4 GSK* 455 2.28
2.2 GLENMARK 427 2.14
2.0 (IPCA) 411 2.06
USV 373 1.87
1.8
(MICRO *) 323 1.62
1.6
PFIZER* 297 1.49
1.4
ALEMBIC 274 1.37
1.2

1.0

0.8

0.6
Oct’23 Nov’23 Dec’23 Jan’24 Feb’24 Mar’24 Apr’24 May’24 Jun’24 Jul’24 Aug’24 Sep’24 Oct’24

• Emcure*, GSK*, Glenmark, USV, Pfizer* & Alembic have shown improvement in MS for Oct'24 as compared to Sep’24
• Aristo*, Zydus*, IPCA & Micro* reflected dip in MS for Oct'24 as compared to Sep'24
.

IQVIA TSA & SSA Dataset Oct'24 6

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

88 DRL 502 7 103

ARISTO* 578 -8
102 ZYDUS* 455 6 101
ZYDUS* 562 7
97 GLENMARK 381 7 103
EMCURE* 458 2
93 GSK* 364 -3 93
GSK* 455 -2
Month

Month
103 EMCURE* 363 0 96
GLENMARK 427 8
6 101 IPCA 357 5 101
IPCA 411
5 100 USV 337 6 101
USV 373
2 97 MICRO * 279 3 98
MICRO * 323
3 98 ALEMBIC 247 -5 91
PFIZER* 297
-5 90 PFIZER* 230 -2 94
ALEMBIC 274

ZYDUS* 6,462 7 100 ARISTO* 5,806 2 96

ARISTO* 6,422 2 96 ZYDUS* 5,214 6 99
GSK* 5,205 0 94 GLENMARK 4,243 12 105
EMCURE* 5,125 5 98 GSK* 4,170 -1 93
MAT

104 4 97

MAT
GLENMARK 4,772 11 EMCURE* 4,066
IPCA 4,605 13 105 IPCA 3,979 13 106
USV 4,332 6 100 USV 3,914 8 101
MICRO * 3,532 2 95 MICRO * 3,029 2 96
PFIZER* 3,357 -1 93 ALEMBIC 2,900 2 95
ALEMBIC 3,215 1 95 PFIZER* 2,508 -5 89

• TSA & SSA : Glenmark showed the highest growth at month level, while for MAT, IPCA has posted highest growth

IQVIA TSA & SSA Dataset Oct'24

7
 Top Companies #21-30 Market Share Trend
1.40
TSA Val Oct'24 MS Oct'24
1.35
1.30 ERIS* 253 1.27
1.25 (JB PHARMA*) 225 1.13
1.20 (FDC) 218 1.09
1.15 188 0.94
(SANOFI*)
1.10
(HIMALAYA) 156 0.78
1.05
AJANTA 147 0.74
1.00
0.95 (LA RENON) 135 0.68
0.90 (CADILA) 128 0.64
0.85 (FRANCO) 127 0.63
0.80 122 0.61
INDOCO*
0.75
0.70
0.65
0.60
0.55
0.50
Oct’23 Nov’23 Dec’23 Jan’24 Feb’24 Mar’24 Apr’24 May’24 Jun’24 Jul’24 Aug’24 Sep’24 Oct’24

• Eris* & Indoco* have shown improvement in MS for Oct'24 as compared to Sep’24
• Ajanta has maintained MS in the month of Oct’24
• JB*, FDC, Sanofi, Himalaya, La Renon, Cadila & Franco reflected dip in MS for Oct'24 as compared to Sep'24

IQVIA TSA & SSA Dataset Oct'24 8

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

99 ERIS* 209 5 100

ERIS* 253 4
106 FDC 201 5 101
JB PHARMA* 225 12
4 99 JB PHARMA* 198 12 107
FDC 218
-3 92 SANOFI* 164 -3 92
SANOFI* 188
Month

Month
3 98 HIMALAYA 141 4 100
HIMALAYA 156
9 104 AJANTA 130 8 104
AJANTA 147
7 102 FRANCO 118 6 101
LA RENON 135
-8 88 INDOCO* 110 2 98
CADILA 128
5 100 LA RENON 110 9 104
FRANCO 127
3 98 CADILA 105 -9 87
INDOCO* 122

ERIS* 3,006 100 ERIS* 2,468 6 100

6
JB PHARMA* 2,636 104 JB PHARMA* 2,324 12 105
11
FDC 2,417 102 FDC 2,225 9 102
9
SANOFI* 2,284 98 SANOFI* 1,999 7 100
5
MAT

99 100

MAT
HIMALAYA 1,808 HIMALAYA 1,616 6
6
AJANTA 1,742 102 AJANTA 1,550 10 103
9
LA RENON 1,647 110 LA RENON 1,336 17 110
17
CADILA 1,571 93 CADILA 1,299 0 94
-1
CORONA 1,391 106 FRANCO 1,224 -9 85
13
FRANCO 1,319 85 CORONA 1,171 13 106
-9

• TSA & SSA : JB Pharma* showed the highest growth at month level, while for MAT, La Renon has posted highest growth

IQVIA TSA & SSA Dataset Oct'24

9
 Top Companies #31-40 Market Share Trend
0.68
0.66 TSA Val Oct'24 MS Oct'24
0.64 CORONA 120 0.60
0.62 HETERO* 117 0.59
0.60 (BLUE CROSS) 109 0.55
0.58 109 0.54
P&G HLTH
0.56
SYSTOPIC 101 0.51
0.54
(WIN MEDICARE) 85 0.43
0.52
FOURRTS 84 0.42
0.50
(MEDLEY) 83 0.41
0.48
(H&H) 80 0.40
0.46
0.44 (BHARAT SERUM) 78 0.39
0.42
0.40
0.38
0.36
Oct’23 Nov’23 Dec’23 Jan’24 Feb’24 Mar’24 Apr’24 May’24 Jun’24 Jul’24 Aug’24 Sep’24 Oct’24

• Hetero & P&G Hlth have shown improvement in MS for Oct'24 as compared to Sep’24
• Corona, Systopic & Fourrts have maintained MS in the month of Oct’24.
• Blue Cross, Win Medicare, Medley, H&H & Bharat Serum reflected dip in MS for Oct'24 as compared to Sep’24

IQVIA TSA & SSA Dataset Oct'24 10

 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

CORONA 120 9 104 CORONA 101 9 104

HETERO* 117 0 95 BLUE CROSS 100 -7 89
BLUE CROSS 109 -7 89 P&G HLTH 99 6 101
P&G HLTH 109 6 101 SYSTOPIC 91 8 103
Month

Month
SYSTOPIC 101 7 102 HETERO* 89 -4 92
WIN MEDICARE 85 -2 93 MEDLEY 77 -7 89
FOURRTS 84 4 99 WIN MEDICARE 74 -3 93
MEDLEY 83 -7 88 FOURRTS 72 4 99
H&H 80 -1 94 H&H 68 -2 93
BHARAT SERUM 78 11 105 APEX 67 1 97

HETERO* 1,298 8 101 INDOCO* 1,167 0 94

INDOCO* 1,294 0 94 BLUE CROSS 1,114 -3 91
BLUE CROSS 1,217 -3 91 P&G HLTH 1,067 -2 92
P&G HLTH 1,171 -2 92 SYSTOPIC 1,043 11 104
MAT

103 97

MAT
SYSTOPIC 1,162 10 HETERO* 1,002 3
MEDLEY 1,039 2 96 MEDLEY 974 2 96
WIN MEDICARE 972 3 97 WIN MEDICARE 847 3 97
FOURRTS 957 8 102 FOURRTS 825 9 102
H&H 934 4 97 H&H 800 3 96
BHARAT SERUM 906 9 102 WALLACE 767 6 99

• TSA: Bharat Serum showed the highest growth at month level, while for MAT, Systopic has posted highest growth followed by Bharat Serum
• SSA: Corona showed the highest growth at month level, while for MAT, Systopic has posted highest growth followed by Fourrts

IQVIA TSA & SSA Dataset Oct'24

11
 Top Companies #41-50 Market Share Trend
0.44

0.42 TSA Val Oct'24 MS Oct'24

0.40 (APEX) 76 0.38

JANSSEN 74 0.37
0.38
SAMARTH 74 0.37
0.36 73 0.37
(MEYER)
0.34 (ASTRA) 72 0.36
(WALLACE) 71 0.36
0.32
RAPTAKOS 67 0.34
0.30
MSD* 59 0.30
0.28 CENTAUR 58 0.29
0.26 PHARMED 57 0.29

0.24

0.22

0.20
Oct’23 Nov’23 Dec’23 Jan’24 Feb’24 Mar’24 Apr’24 May’24 Jun’24 Jul’24 Aug’24 Sep’24 Oct’24

• Samarth, MSD* & Centaur have shown improvement in MS for Oct'24 as compared to Sep’24
• Janssen, Raptakos & Pharmed have maintained MS in the month of Oct'24
• Apex, Meyer, Astra & Wallace reflected dip in MS for Oct'24 as compared to Sep'24

IQVIA TSA & SSA Dataset Oct'24 12

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

WALLACE 64 7 102
APEX 76 1 96
MEYER 63 5 100
JANSSEN 74 2 97
RAPTAKOS 57 4 99
SAMARTH 74 16 111
BHARAT SERUM 57 10 105
MEYER 73 4 99
Month

Month
CENTAUR 54 -3 93
ASTRA 72 24 118
NUTRICIA 51 27 122
WALLACE 71 6 101
PHARMED 50 10 106
RAPTAKOS 67 4 99
JANSSEN 49 8 104
MSD* 59 1 97
ASTRA 49 30 124
CENTAUR 58 -2 93
BOEHRINGER 48 -9 87
PHARMED 57 9 104

ASTRA 879 30 122 APEX 741 1 95

JANSSEN 866 8 101 MEYER 722 3 96
WALLACE 849 5 98 RAPTAKOS 664 3 97
MEYER 848 3 97 BHARAT SERUM 635 7 100
MAT

7 100

MAT
APEX 838 1 95 PHARMED 576
SAMARTH 775 14 107 CENTAUR 576 1 94
RAPTAKOS 769 4 97 ASTRA 573 27 119
MSD* 741 0 94 JANSSEN 572 4 97
MERCK 676 25 117 BOEHRINGER 570 -5 89
PHARMED 665 6 100 NUTRICIA 544 23 115

• TSA: Astrazeneca showed the highest growth at month & MAT

• SSA: Astrazeneca showed the highest growth at month & MAT

IQVIA TSA & SSA Dataset Oct'24

13
 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

6 0.38 0.21
FORACORT 75 TELMA 42 6
-1 0.36 0.21
AUGMENTIN 73 MANFORCE 41 14
0 0.34 0.20
GLYCOMET-GP 69 INFLUVAC 40 89
Top 1-10

Top 21-30
-2 0.34 0.20
MIXTARD 68 T-BACT 39 19
-26 0.31 0.20
MONOCEF 61 CALPOL 39 -26
10 0.30 0.20
PAN 59 CILACAR 39 22
16 0.29 0.19
UDILIV 58 SHELCAL 37 1
12 0.29 0.18
THYRONORM 57 ULTRACET 37 6
-3 0.27 0.18
CLAVAM 54 ECOSPRIN-AV 36 10
20 0.27 0.18
PAN-D 54 MOXIKIND-CV 36 -6

AZITHRAL 36 -24 0.18

LIV-52 53 -2 0.27
LEVIPIL 36 1 0.18
RYZODEG 53 19 0.27
0.18
Top 11-20

ZERODOL-SP 52 3 0.26 RYBELSUS 35 44

Top 31-40
0.24 DUPHALAC 35 25 0.17
BETADINE 49 1
DUOLIN 48 13 0.24 ZIFI 34 -3 0.17
LANTUS 46 -1 0.23 PANTOP 32 -10 0.16
DEXORANGE 45 8 0.23 ZINCOVIT 32 10 0.16
ROSUVAS 44 23 0.22 NOVOMIX 32 7 0.16
DOLO 43 -5 0.22 TAXIM-O 32 0 0.16
BUDECORT 43 -1 0.22 TELMA-H 31 8 0.16

• Foracort is the topmost brand with 75 Crs of sales & MS of ~0.38% for the month Oct'24

• Amongst the top 10 brands, Pan-D has shown highest growth followed by Udiliv for the month Oct'24

IQVIA TSA & SSA Dataset Oct'24 14

 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Oct'24 Month (in comparison to Sep'24 Month)

• Foracort is No 1 position brand at month level with a growth of 6%

• Amongst the top 10 Brands, highest growth of 20% is observed by Pan-D
• Pan-D, Telma & Manforce gained 1 rank to secure10th,21st & 22nd positions with a growth of 20%, 6% & 14% respectively
• Glycomet-GP, Udiliv, Duolin & Rosuvas gained 2 ranks to secure 3rd,7th,15th & 18th position with a growth of 0.2%, 16%, 13% &
23%respectively
• Budecort gained 4 ranks to reach 20th position with a growth of -1%
• T-Bact gained 18 ranks to reach 24th position with a growth of 19%
• Influvac gained 29 ranks to reach 23rd position with a growth of 89%

IQVIA TSA & SSA Dataset Oct'24 15

 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Oct'24 (in comparison to Sep'24), amongst In the month of Oct'24 (in comparison to Sep'24), amongst
the Top 25 companies the Top 25 companies
• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%
• Emcure* & Glenmark improved by 1 rank each to reach 13th & • GSK* & Emcure* improved by 1 rank each to reach 14th & 15th
15th positions respectively positions respectively
• Torrent* improved by 2 ranks to reach 7th position • Torrent* & Eris* improved by 2 ranks each to reach 6th & 21st
positions respectively

As per MAT Oct'24 (in comparison to MAT Sep'24), amongst

the Top 25 companies As per MAT Oct'24 (in comparison to MAT Sep'24), amongst
• Sun* has maintained its top position in the IPM with a market the Top 25 companies
share of 8% • Sun* has maintained its top position in the IPM with a market
• Zydus* improved by 1 rank to reach 11th position share of 8%
• Lupin & DRL improved by 1 rank each to reach 7th & 10th
positions respectively

IQVIA TSA & SSA Dataset Oct'24 16

 Indian / MNC trends % Growth Over Same Month Last Year Indian MNC
12 10.7
10.3
9.410.0 11.7
10 9.8
8.4
7.8 7.4 7.5
8 7.8 7.8
5.7 6.6
6 6.9
Month Growth

5.3 4.7
3.9 6.1
4 5.0
1.9
2
2.2
0 1.4 -0.6

-2
NOV’23 DEC’23 JAN’24 FEB’24 MAR’24 APR’24 MAY’24 JUN’24 JUL’24 AUG’24 SEP’24 OCT’24

Value (Rs. Crs)

Indian MNC

18,021 18,089 17,962 18,009 17,415 19,661 19,006 17,782 19,921 20,181 20,213 19,957
Share in IPM

84% 84% 84% 84% 83% 83% 84% 84% 84% 84% 84% 84%

16% 16% 16% 16% 17% 17% 16% 16% 16% 16% 16% 16%

NOV’23 DEC’23 JAN’24 FEB’24 MAR’24 APR’24 MAY’24 JUN’24 JUL’24 AUG’24 SEP’24 OCT’24

• Indian companies registered growth of 4.7% whereas MNC’s registered growth of 6.6% for the month

IQVIA TSA & SSA Dataset Oct'24 17

 Acute / Chronic Trends
ACUTE CHRONIC
14 13 12
12 12 11 11
11 10 10
10 9
8 8 8
8 7
Growth (%)

7 6 6
6 5 7
7
4 4
2
2 3 2
-1
0
-2
NOV’23 DEC’23 JAN’24 FEB’24 MAR’24 APR’24 MAY’24 JUN’24 JUL’24 AUG’24 SEP’24 OCT’24

Gwth %
4.2% 9.3% -3.0% -14.1% 10.0%
Top 5 TC 4s

291
244 229 226
Value (Rs 212
Crs)

GLIMEPIRIDE+METFORM. FOOD SUPPLEMENTS AMOXY. & CLAV. SOLIDS COUGH PREP. ETHICALS INTER.-ACTING+FAST ACTING

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 69 ALKEM* 40 GSK* 51 GLENMARK 37 ABBOTT* 152

LUPIN 33 APEX 33 ALKEM* 36 DRL 27 LUPIN 31

SUN* 29 SUN* 21 MANKIND 33 MANKIND 20 CIPLA 11

• Acute has shown growth of 2% whereas Chronic has shown growth of 10% for the month

IQVIA TSA & SSA Dataset Oct'24 18

 Top Therapy Trends
TSA

Value_Oct'24 (Rs. Crs) % Gwth SPLY Value_Oct'24 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 135 16 J01C0G AMOXY. & CLAV. SOLIDS 229 -3

C02C04 TELMISARTAN 107 5 J01D0C CEFTRIAXONE INJECTABLS 163 -18
14

Anti-Infectives
C02F06 AMLODIPINE+TELMISARTAN 100 J01N01 MEROPENEM 125 8
C02G0H TELMISARTAN + HCT 78 7 J01C0H AMOXY. & CLAV. LIQUIDS 117 -2
Cardiac

C10A03 ATORVASTATIN 77 7 J01D0Z CEFTRIAXONE+SULBACTAM 112 -7

B01A0E ENOXAPARIN 73 11 J01D0L CEFIXIME ORAL SOL. 96 -10
C01D0B CILNIDIPINE 70 18 J01F04 AZITHROMYCIN ORAL SOLIDS 93 -17
C02F02 ATENOLOL+AMLODIPINE 61 9 J01K05 PIPERACILLIN+TAZOBACTAM 90 0
C02F0Y SACUBITRIL + VALSARTAN 60 27 J01D0V CEFPODOXIME SOLIDS 80 -18
C02F0I METOPROLOL+TELMISARTAN 60 11 J01D0I CEFUROXIME ORAL SOLIDS 77 -1

A02B0Q PANTOPR.+ DOMPERID. 148 8 A10B0Q GLIMEPIRIDE+METFORM. 291 4

A02B0A PANTOPRAZOLE SOLIDS 108 7 A10C03 INTER.-ACTING+FAST ACTING 212 10

A02B0R RABEPRA.+ DOMPERID. 107 1 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 111 5

Anti Diabetic
A02B0S ESOMEPR.+ DOMPERID. 82 29 A10C05 LONG ACTING 98 9

-3 A10C01 FAST ACTING 85 16

GI

A07L01 ORAL ELECTROLYTES 82

A07K09 OTHERS 75 15 A10B0D METFORMIN + VILDAGLIPTIN 76 2

A02A05 ANTACID+ANTIFLATU.LIQ 69 15 A10B07 METFORMIN + SITAGLIPTIN 73 15

A06A0A LACTULOSE 61 15 A10B0W PIOGLITAZ.+METFORM.+GLIM. 68 8

A06A07 MILK OF MAG AND COMB. 60 12 A10B12 DAPAGLIFLOZIN 54 14

A02B0B PANTOPRAZOLE INJ. 56 -10 A10B0M GLICLAZIDE + METFORMIN 49 10

• In Cardiac, Sacubitril+Valsartan posted highest growth of 27%

• In AI, Execept Meropenem all other subgroups are degrowing
• In GI, Esomep+Domperidone posted highest growth of 29%
• In Anti diabetic, Glimepride+Metformin registered highest sales of 291 Cr with a growth of 4%

IQVIA TSA & SSA Dataset Oct'24 19

 Top Therapy Trends
TSA

Value_Oct'24 (Rs. Crs) % Gwth SPLY Value_Oct'24 (Rs. Crs) % Gwth SPLY

R05B01 COUGH PREP. ETHICALS 226 -14 M02A01 NSAIDS 90 2

R03C0R FORMOTERAL+BUDESONIDE 125 5 N02B05 PARACETAMOL ORAL SOLIDS 89 -16
R03B01 LEVOCETIRIZ.+MONTELU SOLD 114 -3 M01A0G PARACE.+ACECLOF.+SERRAPE. 84 6
Respiratory

R05B05 LEVOSALBUTAMOL & COMB. 105 -10 M05C02 CALCITRIOL COMB. 75 -4

Pain
R05A02 COLD PREP. LIQUIDS 89 -8 N02B07 PARACETAMOL INJECTIONS 67 10
R05B07 CHLORPHNMN+DEXTROMETHRPHN 68 -11 M05B0C COLLAGEN COMB 53 14
R03C0S IPRATROPIUM + LEVOSALBU. 57 11 N02B0K PARACETAMOL + TRAMADOL 49 5
R03C02 BUDESONIDE 55 0 N02B06 PARACETAMOL ORAL LIQUIDS 49 -12
R05A01 COLD PREP. SOLIDS 55 -5 M01A0U ACECLOFENAC + PARACETAMOL 46 -1
R03B02 MONTELUKAST+FEXOFENADINE 36 -3 M04A03 FEBUXOSTAT 41 20

V06E01 FOOD SUPPLEMENTS 244 9 D02A01 EMOLLIENTS,PROTECTIVES 153 7

V06C01 INFANT FORMULAS 127 25 D01C03 ITRACONAZOLE 99 11
A11F02 MECOBALAMIN COMB. 116 1 D11A09 OTH.DERMATOLOGICAL PREP. 65 12
A11C02 PLAIN VIT.D 99 8 D06A08 MUPIROCIN 49 16
2

Derma
A12A04 CALCIUM + COLECALCI. SOLI. 90 D01A02 LULICONAZOLE 45 10
VMN

A12A01 CALCIUM ORAL SOLIDS 83 5 D02B01 SUNSCREENS 43 16

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 68 -3 D01A04 CLOTRIMAZOLE 29 31
V06E05 ADULT WELLNESS 48 7 D07D0C CLOBET+MICONAZOL+NEOMYCIN 28 -9
A11A05 OTH. MULTIVIT.-MIN. LIQUIDS 45 0 D16A0D OTH HAIR CARE PREPS. 27 11
A15A01 APPETITE STIMULANTS 45 -6 D02C07 HYDROQU.+TRETI.+MOMETA. 24 -8

• In Respiratory therapy, all categories degrowing except Formoteral+Budesonide & Ipra+Levosalbutamol

• In Pain market, Paracetamol solids & liquids degrowing along with Calcitrol comb
• In VMN, Infant formulas is the fastest growing segment at 25%
• 7 out of 10 top 10 subgroups in Derma growing in double digit growth rates while 2 low contributing subgroup degrowing

IQVIA TSA & SSA Dataset Oct'24 20

 Top Therapy Trends
TSA

Value_Oct'24 (Rs. Crs) % Gwth SPLY Value_Oct'24 (Rs. Crs) % Gwth SPLY

N03A0T LEVETIRACETAM 98 6 B03A01 CONV.IRON SOLIDS 127 6

N06C02 ESCITALOPRAM+CLONAZEPAM 48 10 B03A02 CONV.IRON LIQUID 114 0
N03A0V GABAPENTIN + NORTRIPTYLIN 47 15 G03D04 DYDROGESTERONE 100 7
Neuro/CNS

Gynaec
N07C01 BETAHISTINE 40 2 B03A03 CONV.IRON INJ. 77 3
N07A01 PREGABALIN 30 5 G03D03 PROGESTERONE 75 7
N03A0J OXCARBAZEPINE 29 9 G03G06 HUMAN MENOPAUSAL GONADOTROP. 41 7
N03A10 BRIVARACETAM 27 34 G02C01 OTHER GYNAECO.PREP. 35 1
N03A0I NORTRIPTYLINE+PREGABALIN 26 5 G03D02 NORETHISTERONE 27 6
N07A02 PREGABALIN+MECOBALAMIN 25 1 G03K02 MIFEPRISTONE+MISOPROSTOL 26 -13
N03A04 SODIUM VALPROATE ORAL SOLIDS 24 6 G03G05 HUMAN CHORIONIC GONADOTROP. 26 -4

L01G09 OTH.MAB.ANTINEOPLASTICS 48 21 V03D04 SILDENAFIL 45 6

L01G02 TRASTUZUMAB RECOMBINANT 36 23 G03J0A DUTASTERIDE + TAMSULOSIN 42 19
L01H09 OTH.PKI.ANTINEOPLASTICS 30 20 G03J0G DUTASTERIDE + SILODOSIN 40 20
Antineoplast

L01G01 RITUXIMAB 27 8 G04B09 OTH. UROLOGICAL PREP. 32 8

Urology
L01G03 BEVACIZUMAB RECOMBINANT 26 46 G03J03 TAMSULOSIN 27 11
L01C01 PACLITAXEL 20 -1 G03J0E SILODOSIN 23 12
L04X06 MYCOPHENOLIC ACID 15 7 G04B01 URINARY ALKALISERS 22 2
L03A01 FILGRASTIM 14 57 G04B0D ALPHA KETOANALOGUE 20 27
L01B05 METHOTREXATE 14 12 V03D05 TADALAFIL 20 12
L04X01 MYCOPHENOLATE MOFETIL 13 11 G04B02 FLAVOXATE 18 22

• In Neuro therapy, Levetiracetam is the top contributing subgroup with 98 Cr of sales with a growth of 6%
• In Gynaec therapy, Conv iron solids, liquids and inj. together have contributed to ~318 Cr of sales
• In Antineoplast therapy, Filgrastim posted highest growth of 57%
• In Urology therapy, Alpha Ketoanalogue posted highest growth of 27%

IQVIA TSA & SSA Dataset Oct'24 21

 Key changes
PTR Changes (Top 50 brands) New Introduction

➢ Total number of SKUs with PTR changes in Oct'24 are 2939. ➢ 698 new packs were Introduced in Oct'24
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Foracort, Mixtard, Augmentin, Thyronorm,
Clavam, Duolin, Manforce, Azithral, Aciloc, Telma-AM, Mikacin, Volini.

New Lab & Corporate Brand Transfer

➢ 15 new labs has been introduced in Oct'24 dataset ➢ 70 brand transfer registered in Oct'24

IQVIA TSA & SSA Dataset Oct'24 22

THANK YOU